

The Extract of *Portulaca oleracea* and Its Constituent, Alpha Linolenic Acid Affects Serum Oxidant Levels and Inflammatory Cells in Sensitized Rats

Mahsa Kaveh¹, Akram Eidi¹, Ali Nemati², and Mohammad Hossein Boskabady^{3,4}

¹ Department of Biology, Sciences and Research Branch, Islamic Azad University, Tehran, Iran

² Department of Biochemistry and Biophysics, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran

³ Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁴ Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Received: 27 September 2016; Received in revised form: 13 December 2016; Accepted: 5 February 2017

ABSTRACT

The effects of *Portulaca oleracea* and its constituent, alpha linolenic acid on serum oxidant levels and inflammatory cells in sensitized rats were examined.

Eight groups of rats including control, sensitized, sensitized rats treated with 1, 2 and 4 mg/mL extract of *P. oleracea*, 0.2 and 0.4 mg/mL alpha linolenic acid (ALA) and 1.25 µg/mL dexamethasone were studied serum levels of superoxide dismutase (SOD), catalase (CAT), thiol groups, NO₂, NO₃, and Malondialdehyde (MDA) as well as total and differential WBC in blood were measured.

Serum concentrations of SOD, CAT and thiol were significantly decreased but NO₂, NO₃ and MDA as well as total WBC number and percentages of eosinophil and neutrophil were increased in sensitized group ($p < 0.001$ for all cases). Treatment of sensitized animals with dexamethasone, high concentrations of the extract and ALA improved all measured variables except monocyte for all three treatment groups and eosinophil for dexamethasone treatment ($p < 0.01$ to $p < 0.001$). In addition, treatment with low and medium extract and low ALA concentrations improved serum levels of NO₂, NO₃ and total WBC count ($p < 0.001$ for all cases). Neutrophil and lymphocyte percentages and serum level of thiol also improved due to treatment with medium extract and low ALA concentration ($p < 0.01$ to $p < 0.001$). Medium extract and low ALA treatment also caused improvement of serum level of CAT and eosinophil percentage as well as SOD level respectively ($p < 0.01$ to $p < 0.001$).

The effect of the extract of *P. oleracea* and ALA on serum oxidants and inflammatory cells were demonstrated in sensitized rats, which was comparable with dexamethasone effects at used concentrations.

Keywords: Alpha linolenic acid; Oxidant and antioxidant levels; *Portulaca oleracea*; Sensitized rats; White blood cell

Corresponding Author: Mohammad Hossein Boskabady, MD, PhD; Neurogenic Inflammation Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran. Tel: (+98 51) 3882 8565; Fax: (+98 51) 3882 8564, E-mail: boskabadyh@mums.ac.ir;

INTRODUCTION

Bronchial asthma is a chronic inflammatory illness, in which various cells including mast cells, eosinophils,

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat

and T lymphocytes, and other cellular components contribute.¹ These inflammatory cells produce several mediators including a range of toxic reactive oxygen species (ROS), such as superoxide radical, hydrogen peroxide, hypochlorous acid, and hydroxyl radical that modulate the inflammatory response.²⁻⁵ There are several antioxidants in the lung and blood including glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), catalase, glutathione, vitamin E, and vitamin C⁶⁻⁹, which prevent oxidant-mediated toxicity. The oxidative stress in asthma was shown by increased production of lipid peroxidation products and protein carbonyls in plasma,¹⁰ increased plasma isoprostanes¹¹, enhanced generation of ROS by blood monocytes, neutrophils, and eosinophils,^{12, 13} increased oxidized glutathione in bronchoalveolar lavage (BAL) fluid¹⁴ and increased production of nitric oxide (NO) in exhaled air.¹⁵ Physiological antioxidant system is also impaired in asthma, possibly because of inflammation. Thus, the imbalance between oxidants and antioxidants that is called oxidative stress is critical in asthma pathogenesis.¹⁶ Oxidative stress and inflammatory mediators are contributing mechanisms in pulmonary diseases such as asthma. These two mechanisms alters the production of the oxidants and cause structural damage of the lung.¹⁷

Portulaca oleracea (*P. oleracea*) L. is a warm-climate and annual plant which belongs to the Portulacaceae family.¹⁸ This plant exhibits a wide range of pharmacological effects, including anti-inflammatory¹⁹, antioxidant²⁰, and wound-healing²¹ properties. Moreover, skeletal muscle relaxant effect of this plant has been reported.²² The relaxant effects of the plant on tracheal smooth muscle^{23, 24}, potent bronchodilatory effects in the airways of asthmatic patients²⁵ and its antitussive effect²⁶ have been studied previously. The effect of *P. oleracea* on Th1/Th2 balances was also demonstrated, which may suggest its therapeutic value in inflammatory disease associated with decreased Th1/Th2 balance such as asthma.²⁷ *P. oleracea* also provides a source of nutritional benefits owing to its rich omega-3 fatty acids and antioxidant properties.²⁸

The plant was studied for its ability to reduce oxidative stress induced by vitamin A deficiency.²⁹ It was demonstrated that phenolic alkaloids of the plant served as a new class of antioxidant agents.³⁰ The majors constituents of the plant are flavonoids, alkaloids, coumarins, monoterpene glycoside and fatty

acids as well as alpha-linolenic acid (omega-3).^{31,32} Alpha linolenic acid (ALA) is an omega-3 fatty acid, which plays an important role in human growth and development and in preventing diseases.³³ ALA can modulate the immune response of the epidermis by influencing T lymphocytes, acting on toll-like receptors (TLRs), and activating caspase cascades that influence many inflammatory dermatoses, including atopic dermatitis, systemic lupus erythematosus, and skin cancer.³⁴ ALA increases the level of eicosapentaenoic acid (EPA) in the phospholipids of cell membranes and decrease the synthesis of proinflammatory cytokines such as interleukin-1 and TNF- α in mononuclear cells of the human body. These changes resulted in reducing the severity of the response to allergens in asthma disease.^{35,36}

With regard to existence of airway inflammation and oxidative stress in asthma and due to anti-inflammatory property of *P. oleracea* and its constituent ALA, in the present study, the effects of the plant and ALA on inflammatory cells and serum oxidant levels in sensitized rats were examined.

MATERIAL AND METHODS

Animal Groups and Animal Sensitization

Eight groups of rats were studied in random order including: control or non-sensitized animals (group C), untreated asthma animals (group S), S groups treated with 1, 2 and 4 mg/mL extract of *P. oleracea* (groups P1, P2 and P4, respectively), S groups treated with 0.2 and 0.4 mg/mL ALA (groups A0.2 and A0.4, respectively) and S groups treated with 1.25 μ g/mL dexamethasone (group D), (n= 4 for ALA treated groups and n=8 for other groups) (Table 1). The extract, ALA and dexamethasone were administered during sensitization period in animals' drinking water. The animals of C and S groups were given drinking water alone. There was no significant difference in the used drinking water between different groups (each rat used averagely 40 mL/day drinking water).

Animals (Male Wistar rats weighing 220 ± 25 g) were kept at $24 \pm 2^\circ\text{C}$ with relative humidity of 44-56 % and sensitized on days 1, 2 and 3 by intraperitoneal injections of 1mg/kg ovalbumin (OVA) + 100 mg Al(OH)₃ as adjuvant. OVA and Al(OH)₃ were added in 1 mL of 0.9% sterile saline and was shaken vigorously and immediately injected. Animals were exposed to 1% OVA aerosol for 20 min with an air flow of 8 L/min

Table 1. Various experimental animal groups used for the evaluation of anti-oxidant and anti-inflammatory effect of *Portulaca oleracea*

Groups	Definition		Abbreviate name	n
Sensitized (asthma)	Non-treated sensitized group		Group S	8
Treated groups	Treated with <i>P. oleracea</i> extract	1 mg/mL	Group P1	8
		2 mg/mL	Group P2	8
		4 mg/mL	Group P4	8
	Treated with alpha linolenic acid (ALA)	0.2 mg/mL	Group A0.2	4
		0.4 mg/mL	Group A0.4	4
	Treated with Dexamethasone	1.25 µg/mL	Group D	8
Control	non-sensitized		Group C	8

Sensitization of rats were done by intraperitoneal and inhaled ovalbumin. In treated groups, the extract, ALA or dexamethasone were administered in their drinking water during sensitization period.

produced by a DeVilbiss PulmoSonic nebulizer (DeVilbiss Health Care Ltd, Feltham, UK) on days 6, 9, 12, 15, 18 and 21 in a 0.8 m³ chamber, with animal normal-breathing. Rats were housed in a caging system with clean filtered air (Maximiser, Thorens Caging System Inc, Hazleton, PA, USA).³⁷ Temperature was maintained at 22 ± 2°C on a 12 h light/dark cycle and water and food available *ad libitum* during experimental period.

Plant and Extracts

P. oleracea was collected from Sabzevar city, Khorasan Razavi province, Iran, in July. A voucher sample was preserved for reference in the herbarium of the school of pharmacy, Mashhad University of Medical Sciences (Herbarium No: 240-1615-12). The leaves of this plant were came apart and dried in shadow. The extract was obtained by maceration method. For preparation of hydro-ethanolic extract, 100 g of *P. oleracea* powder in 1000 mL ethanol 70% was macerated in laboratory temperature for 72 h. To prepare the dry extract, the solution was dried by rotary evaporator and the solvent was isolated. The yield extract was 17.5%. Finally, the extract concentration was adjusted to 10 mg/mL by adding distilled water to the dried extract.²⁷

Measurement of Serum Antioxidant Levels

Five mL of blood samples was taken by cardiac puncture immediately after sacrificing and exposing the animal's chest on day 22 study. For measurement of

oxidant, antioxidant markers, blood samples were collected into test tube and placed at room temperature for 1 h. The samples were then centrifuged at 3500 g for 10 min. The supernatant was collected and immediately stored at -70 °C until analyzed. For evaluation of total and differential white blood cells, two mL of blood sample was collected into the test tube containing anticoagulant ethylenediaminetetraacetic acid (EDTA).

Thiol

Serum thiol concentration was measured using 2, 2'-dinitro-5, 5'-dithiodibenzoic acid (DTNB), which reacts with the thiols. The product has a yellow-colored complex with a peak absorbance at 412 nm. Fifty micro liter serum supernatant was added to 1 mL Tris-EDTA buffer (pH 8.6) in 1 mL cuvettes and sample absorbance was read at 412 nm against Tris-EDTA buffer alone (A1). 20 micro liter DTNB reagents (10 mmol/L in methanol) were then added to the mixture and after 15 min (stored in laboratory temperature) the sample absorbance was read again (A2). As a blank (B), the absorbance of DTNB reagent was also read. Total thiol concentration (mmol/L) was calculated from the following equation:³⁸

$$(A2-A1-B) \times 1.07 / 0.05 \times 13.6.$$

Superoxide Dismutase (SOD)

Measurement of SOD activity was performed by colorimetric assay involving generation of superoxide by pyrogallol auto-oxidation and the inhibition of superoxide-dependent reduction of the tetrazolium dye,

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat

MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) to its formazan by SOD at 570 nm.³⁹ SOD activity of I unit was defined as the amount of enzyme causing 50% inhibition in the MTT reduction rate.

Catalase (CAT)

CAT activity was estimated using the principle of the assay, which is based on determination of the rate constant, k (dimension: s^{-1} , k) of hydrogen peroxide decomposition.⁴⁰ The decrease in absorbance at 240 nm per minute was measured and the rate constant of the enzyme was determined and activities were expressed as k (rate constant) per liter.

Measurement of Serum Oxidant Levels

Nitric Oxide (NO)

Serum total stable oxidation products of NO metabolism (NO_2^-/NO_3^-) were assessed using a Griess reagent, which consisted of sulfanilamide (SULF) and *N*-(1-Naphthyl)ethylenediamine dihydrochloride (NEDD).⁴¹ The frozen sample was allowed to reach a temperature of 25°C followed by being deproteinized by zinc sulfate solution (Sigma, USA). The liquefied serum was then centrifuged at 12000 g for 10 minutes. Aliquots (300 μ L) of the clear supernatant was mixed with Griess reagents including 300 μ L SULF (2% w/v, Sigma, USA) in 5% HCl and 300 μ L NEDD (0.1% w/v, Sigma, USA) in H₂O in a test tube. For the reduction of nitrate to nitrite, 300 μ L saturated solutions of vanadium (III) chloride (VCl_3 ; Sigma, USA) in 1 M HCl was added and incubated for 2 h at 30°C in the dark. The absorbance of samples was measured at 540 nm against a blank containing the same concentrations of ingredients. Linear regression was used to determine NO concentration from standard curve of $NaNO_2$. The final results were expressed as μ mol.⁴¹

Malondialdehyde (MDA)

MDA levels, as an index of lipid peroxidation reacts with thiobarbituric acid (TBA) as a thiobarbituric acid reactive substance (TBARS). The resultant product has a red-colored complex, which has peak absorbance at 535 nm. One milliliter serum supernatant was added with 2 mL TBA/trichloroacetic acid (TCA)/HCl reagent and the solution was heated in a water bath for 40 min. The solutions were cooled and centrifuged within 1,000 \times g for 10 min. The absorbance was

measured at 535 nm.^{42,43} The MDA concentration was calculated using the equation: $C(M) = \text{Absorbance} / (1.56 \times 105)$.

White blood Cells Count

The blood sample prepared for WBC counting was stained with Turk solution consisted of 1 mL of glacial acetic acid, 1 mL of gentian violet solution 1 % and 100 mL distilled water (1:10 dilution), and total white blood cell (WBC) counted in duplicate in a hemocytometer (in a Burker chamber). Differential cell counts were measured on a thin slide, prepared with a smearing blood sample, staining with Wright-Giemsa's. Differential cell analysis was carried out under a light microscope according to staining and morphological criteria, by counting 100 cells, and the percentage of each cell type was calculated.

Statistical Analysis

Data were presented as means \pm SEM. The data of control, sensitized and treated groups were compared using one way analysis of variance (ANOVA) with Tukey-Kramer's post-test. The results of three concentrations of extract and two concentrations of ALA were also compared using ANOVA with Tukey-Kramer's post-test. The statistical analysis was performed using InStat (GraphPad Software, version 3.06, Inc, La Jolla, USA). p values less than 0.05 were considered as statistical significance.

RESULTS

Antioxidants Markers

Serum concentrations of thiol, SOD and CAT in sensitized group were significantly lower than those of control group ($p < 0.001$ for all cases; Figure 1).

Treatment of sensitized animals with dexamethasone, two higher concentrations of the extract and both concentration of ALA led to significant increase in serum concentration of thiol, treatment with dexamethasone, the highest concentration of the extract and both concentrations of ALA resulted in significant increase in serum concentration of SOD and treatment with dexamethasone, two higher concentrations of the extract and the highest concentration of ALA led to significant increase in serum concentration of CAT compared to sensitized group ($p < 0.01$ to $p < 0.001$; Figure 1). However, serum concentrations of thiol,

SOD and CAT in treated S groups with dexamethasone, all concentrations of extract and ALA were significantly lower compared to control group ($p < 0.001$ for all cases; Figure 1).

The effects of highest extract concentration on thiol, SOD and CAT values and the effects of medium concentration on thiol and CAT values were significantly higher than the effect of low extract concentration ($p < 0.05$ to $p < 0.001$, Table 2). The effect of high ALA concentration on thiol and CAT were also significantly higher than the effect of its low concentration ($p < 0.001$ for both cases, Table 2).

The effect of low concentration of the extract (1 mg/mL) on serum concentration of SOD and the highest concentration of extract (4 mg/mL) on serum concentration of CAT was significantly lower than that of the ALA ($p < 0.01$ for both cases, Table 2).

The effects of two lower concentrations of the extract (1 and 2 mg/mL) on serum level of thiol and SOD and the effects of its all concentrations on CAT were significantly lower than dexamethasone treatment ($p < 0.01$, to $p < 0.001$; Figure 1), The effects of low concentration of ALA (0.2 mg/mL) on serum levels of thiol and CAT also were significantly lower than the

effect of dexamethasone treatment ($p < 0.001$ for both cases; Figure 1a and c).

Oxidants

Serum concentrations of NO_2 , NO_3 and MDA in sensitized group were significantly higher than those of control group ($p < 0.001$ for all cases; Figure 2).

Treatment of sensitized animals with dexamethasone, all concentrations of the extract and ALA led to significant reduction in serum levels of NO_2 and NO_3 ($p < 0.001$ for all cases; Figure 2 a and b). In addition, treatment with dexamethasone, the highest concentration of extract (4 mg/mL) and ALA (0.4 mg/mL) caused significant reduction in serum concentration of MDA compared to untreated sensitized group ($p < 0.001$ for all cases; Figure 2 c). However, serum level of NO_2 in treated group with low extract concentration and NO_3 in all treated groups were still significantly higher than control group ($p < 0.05$ to $p < 0.001$). MDA level in treated groups with two lower extract and low ALA concentrations was also significantly higher than control group ($p < 0.001$ for all cases; Figure 2).

Table 2. Values of serum thiol, SOD, CAT, NO_2 , NO_3 , and MDA concentration in treated groups with three concentrations of *P. oleracea* (S+P), and two concentrations of alpha linolenic acid in sensitized animals (S+A), (n=4 for ALA-treated groups and n=8 for other group)

Groups	Thiol (μM)	SOD (U/mL)	CAT (U/mL)	NO_2 (μM)	NO_3 (μM)	MDA (nM)
S + P1	0.04±0.005	0.008±0.0005	0.017±0.001	3.72 ± 0.1	23.22 ± 0.9	1.07 ± 0.14
S + P2	0.08±0.004	0.013±0.001	0.033±0.01	3.39 ± 0.06	18.09 ± 1.24	0.74 ± 0.09
S + P4	0.16±0.01	0.024±0.003	0.053±0.003	2.51 ± 0.14	15.51 ± 1.24	0.42 ± 0.03
S + A0.2	0.07±0.005	0.018±0.002	0.014±0.002	2.92 ± 0.1	17.48 ± 0.52	0.72 ± 0.04
S + A0.4	0.18±0.01	0.02±0.002	0.077±0.005	2.07 ± 0.05	14.97 ± 0.98	0.4 ± 0.03

Values are presented as mean + SEM. Three concentrations of *P. oleracea* were 1, 2 and 4 mg/mL, two concentrations of alpha linolenic acid were 0.2 and 0.4 mg/mL. SOD; superoxide dismutase, CAT; catalase, MDA; Malondialdehyde.

Statistical significance for the difference between the data of S + A vs S + P: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Statistical significance for the difference between the data of S + P2 and S + P4 vs S + P1, and also S + A 0.4 vs S + A 0.2: + $p < 0.05$, ++ $p < 0.01$, +++ $p < 0.001$.

Statistical significance for the difference between the data of S + P4 vs S + P2: ## $p < 0.01$, ### $p < 0.001$.

The statistical comparisons were made using Tukey–Kramer multiple pot test.

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat




Figure 1. The levels (mean±SEM) of serum (a) thiol, (b) superoxide dismutase (SOD) and (c) catalase (CAT) in control rats (C), sensitized animals (S), S groups treated with dexamethasone (S+D), three concentrations of *P. oleracea* (S+P) and two concentrations of alpha linolenic acid (S+A), (n=4 for ALA treated groups and n=8 for other group).

Statistical significance for the difference between the data of S, S + D, S + P and S + A vs C: *** p<0.001

Statistical significance for the difference between the data of S + D, S+P and S + A vs S:

++ p<0.01, +++ p<0.001

Statistical significance for the difference between the data of versus S+P and S + A vs S+D: ## p<0.01, ### p<0.001. The statistical comparisons were made using Tukey–Kramer multiple pot test.




Figure 2. The serum levels (mean±SEM) of (a) NO₂, (b) NO₃ and (c) malondialdehyde (MDA) in control rats (C), sensitized animals (S), S groups treated with dexamethasone (S + D), three concentrations of *P. oleracea* (S + P) and two concentrations of alpha linolenic acid (S+A), (n=4 for ALA treated groups and n=8 for other group)

Statistical significance for the difference between the data of S, S+D, S+P and S+A vs C: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Statistical significance for the difference between the data of S+D, S+P and S + A vs S: *** $p < 0.001$

Statistical significance for the difference between the data of S+P and S+A vs S+D : ## $p < 0.01$, ### $p < 0.001$.

The statistical comparisons were made using TukeyKramer multiple pot test.

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat

The effect of highest extract concentration (4 mg/mL) on serum NO₂, NO₃ and MDA values ($p < 0.001$ for all cases) and its medium concentration (2 mg/mL) on NO₃ level ($p < 0.05$) were significantly higher than the effect of its low concentration (1 mg/mL), (Table 2). There was significantly higher reduction in NO₂ level due to treatment with highest compared to medium concentration of the extract ($p < 0.001$, Table 1). The effects of high ALA treatment on NO₂ and MDA values were also significantly higher compared to its low concentration ($p < 0.001$ for both cases, Table 2).

The effects of low concentration of extract (1 mg/mL) on serum level of NO₂ ($p < 0.001$), NO₃ and MDA ($p < 0.05$ for both case) were significantly lower than that of the effects of corresponding concentrations of ALA (Table 2).

The effects of treatment with low extract concentration on NO₂ and NO₃ and the effect of its two lower concentrations (1 and 2 mg/mL) and low ALA (0.2 mg/mL) concentration on MDA values were lower than the effect of dexamethasone treatment ($p < 0.01$, $p < 0.001$; Figure 2). However, the effects of high extract (4 mg/mL) and ALA (0.4 mg/mL) on serum level of NO₂ were higher than dexamethasone treatment ($p < 0.001$ for both cases; Figure 2 a).

Total WBC and Differential WBC

Total WBC number and percentages of eosinophil and neutrophil were significantly increased but lymphocyte percentages was decreased in S group compared to control animals ($p < 0.001$ for all cases; Figures 3 and 4).

Total WBC number in blood of all treated groups and percentages of eosinophil in treated groups with two higher concentrations of the extract (2 and 4 mg/mL) and the highest concentration of ALA (0.4 mg/mL) were significantly decreased compared to sensitized group ($p < 0.01$ to $p < 0.001$). Percentages of neutrophil in treated groups with dexamethasone, two higher concentrations of the extract and all concentrations of ALA were significantly decreased but percentages of lymphocyte were significantly increased compared to sensitized group ($p < 0.001$ for all case; Figures 3 and 4).

However, the percentages of eosinophil in treated groups with dexamethasone, low concentrations of the extract (1mg/mL) and ALA, the percentages of neutrophil in treated groups with dexamethasone and two lower concentrations of the extract were higher, but the percentages of lymphocyte in treated groups with low concentration of the extract was significantly lower than those of control group ($p < 0.05$ to $p < 0.001$; Figures 3 and 4).

Table 3. Values of blood total and differential WBC count in three concentrations of *P. oleracea* (S+P) and two concentrations of alpha linolenic acid (S+A), (n=4 for ALA treated groups and n=8 for other group)

Groups	Total WBC	Eosinophil	Monocyte	Neutrophil	Lymphocyte
S + P1	8312.5±303.37	4.37±0.37	4.5±0.32	31.87±1.0	59.25±0.59
S + P2	7893.75±325.20	1.37±0.32	4.25±0.31	23.25±0.99	71.12±0.61
S + P4	7425±575	1.25±0.31	3.75±0.36	20.87±0.47	74.12±0.97
S + A0.2	8075±1026.4	3±0.40	3.75±0.47	21.25±0.62	72±0.81
S + A0.4	7875±426.96	1±0.4	2.25±0.62	18.75±0.62	78±0.7
		+		+	*++

Values are presented as mean + SEM. The data of WBC is their count in 1 mL blood and those of each type of WBC is the percentage of total WBC. Three concentrations of *P. oleracea* (P) were 1, 2 and 4 mg/mL, two concentrations of alpha linolenic acid were 0.2 and 0.4 mg/mL and that of dexamethasone was 1.25 µg/ mL.

Statistical significance for the difference between the data of S + A vs S+P: * $p < 0.05$, *** $p < 0.001$

Statistical significance for the difference between the data of S + P2 and S+P4 vs S + P1, and also S+A 0.4 vs S + A 0.2: † $p < 0.05$, †† $p < 0.01$, ††† $p < 0.001$

Statistical significance for the difference between the data of S+P4 vs S + P2: ‡ $p < 0.05$

The statistical comparisons were made using Tukey–Kramer multiple pot test.




Figure 3. Values (mean±SEM) of total WBC number in one mL blood (a) and percentages of eosinophil (b) and monocyte (c): in control rats (C), sensitized animals (S), S groups treated with dexamethasone (S + D), three concentrations of *P. oleracea* (S + P) and two concentrations of alpha linolenic acid (S+A), (n=4 for ALA treated groups and n=8 for other group) Statistical significance for the difference between the data of S, S+D, S+P and S+A vs C: ** $p<0.01$, *** $p<0.001$ Statistical significance for the difference between the data of S + D, S + P and S+A vs S: ++ $p<0.01$, +++ $p<0.001$ Statistical significance for the difference between the data of S + P and S + A vs S+D: # $p<0.05$, ## $p<0.01$ The statistical comparisons were made using Tukey–Kramer multiple pot test.

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat




Figure 4. Percentages (mean±SEM) of neutrophil (a) and lymphocyte (b): in control rats (C), sensitized animals (S), S groups treated with dexamethasone (S+D), three concentrations of *P. oleracea* (S+P) and two concentrations of alpha linolenic acid (S+A), (for each group, n=8).

Statistical significance for the difference between the data of S, S+D, S+P and S+A vs C: * $p<0.05$, ** $p<0.01$, *** $p<0.001$

Statistical significance for the difference between the data of S+D, S+P and S+A vs S: +++ $p<0.001$

Statistical significance for the difference between the data of S+P and S+A vs S+D: # $p<0.05$, ### $p<0.001$

The statistical comparisons were made using Tukey–Kramer multiple pot test.

The effects of highest (4 mg/mL) and medium (2 mg/mL) concentrations of the extract on percentages of eosinophil, neutrophil and lymphocyte were significantly higher than its low concentration (1 mg/mL), ($p<0.001$ for all cases, Table 3). The effect of highest concentration of the extract on percentages of lymphocyte was also significantly higher than its medium concentration ($p<0.05$, Table 2). In addition, the effects of high (0.4 mg/mL) concentration of ALA on percentages of eosinophil, neutrophil and

lymphocyte were significantly higher than its low concentration (0.2 mg/mL), ($p<0.05$ to $p<0.01$, Table 3).

The effects of low concentration of the extract (1 mg/mL) on percentages of neutrophil and lymphocyte ($p<0.001$ for both cases) and the effect of its highest concentration (4 mg/mL) on percentages of lymphocyte ($p<0.05$) were significantly lower than that of the ALA (Table 3).

The effects of low concentration of the extract

treatment on percentages of eosinophil ($p < 0.05$), neutrophil and lymphocyte ($p < 0.001$ for both cases) were significantly lower than the effect dexamethasone (Figures 3 and 4). However, The effects of treatment with two higher concentrations of the extract and high concentration of ALA on percentages of eosinophil and the effects of high extract and ALA concentrations on lymphocyte percentages were significantly higher than dexamethasone treatment ($p < 0.05$ to $p < 0.001$; Figures 3b and 4b).

DISCUSSION

The anti-inflammatory and antioxidant effect of *P. oleracea* and its constituent, ALA was reported previously. Therefore, the effect of the extract of this plant and ALA on inflammatory cells and serum oxidant levels in sensitized rats were examined in the present study. Serum concentrations of NO_2 , NO_3 and MDA, total WBC number, and percentages of eosinophil and neutrophil in sensitized animals were significantly higher compared to those of control group. However, thiol, SOD and CAT levels in sensitized group were significantly lower than those of control group.

Increased NO level in exhaled air in asthma and chronic obstructive pulmonary disease was reported previously.⁴⁴ NO is an important mediator in the lung, which may contribute to the inflammatory response in asthma⁴⁵ and is a possible index of oxidative stress in the airway diseases.⁴⁶ It was shown that NO is able to increase the number of Th2 cells and its cytokines, IL-4 and IL-5, which can augment the inflammatory response.⁴⁷ Increase MDA and protein carbonyls in BAL fluid and peripheral blood accompanied with oxidative stress, in asthma have been reported.⁴⁸ In addition, increased MDA level in patients with different airway diseases including asthma, COPD, and bronchiectasis has been reported.⁴⁹ Increased total WBC and eosinophil count have been observed in asthmatic group compared to healthy controls in human.⁵⁰ Increased total and differential WBC count but decreased lymphocytes percentage in sensitized animals were also reported.⁵¹

Increased nitrite, nitrate^{52, 53}, MDA⁵⁴ concentrations and decreased levels of antioxidant parameters (such as SOD, CAT and Thiol)⁵⁵ in asthmatic patients, indicate the role of these agents in pathophysiology of asthma. Physiological antioxidant system is impaired in asthma,

possibly because of inflammation. Thus, the imbalance between oxidants and antioxidants, which is called oxidative stress, is critical to asthma pathogenesis.¹⁶ Increased eosinophil can release a variety of preformed mediators including eosinophil cationic protein, major basic protein, eosinophil derived neurotoxin, eosinophil peroxidase, superoxide ion and lipoxin A, which can contribute in the airway inflammation in asthma.⁵⁶ Increased lymphocytes can also recognize antigen through specific receptors and thereby initiate an inflammatory response by releasing cytokines.⁵⁷

One important component of airway inflammation in asthma is oxidative stress. The production of several oxidizing agents such as superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), and hydroxyl radicals (OH) in macrophages, eosinophils, neutrophils and antigen presenting cells occur in the lung of asthmatic patients. Increased ROS production in asthma is also indicated that can result in lung structural cellular damage through the oxidation of proteins, lipids, and DNA. Increased exhaled markers of oxidative stress such as NO, CO which can lead to cellular injury and pathological changes of the lung is also shown in asthma.⁵⁸ All the above studies support the findings of the present study regarding the process of sensitization of rat (induction of animal model of asthma in rat).

Dexamethasone, a known anti-inflammatory drug, used in the present study as a positive control caused reduction of serum level of NO_2 , NO_3 and MDA, as well as total WBC number and percentages of eosinophil and neutrophil but increased serum values of thiol, SOD and CAT. The inhibitory effect of dexamethasone on airway inflammation and its effect on lymphocytes in asthmatic mice have been reported, which supports the results of our study.⁵⁹

Similar to the effect of dexamethasone, treatment of sensitized animals with hydro-ethanolic extract of *P. oleracea* also showed reduction of serum level of NO_2 , NO_3 and MDA, as well as total WBC number and percentages of eosinophil and neutrophil but increased serum values of thiol, SOD and CAT specially for two higher concentrations of the extract. Treatment of sensitized rats with two concentrations of alpha linolenic acid (ALA), which is one of the main constituent of *P. oleracea* also caused reduction of serum level of NO_2 , NO_3 and MDA, as well as total WBC number and percentages of eosinophil and neutrophil but increased serum values of thiol, SOD and CAT. These results indicate anti-inflammatory

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat

effects of the plant and its constituent, ALA.

Concentration-dependent effects of the extract and ALA on all measured variables were observed in the current study. The effect of highest concentration of the extract on all measured variables except for total WBC and monocyte percentage and the effects of its medium concentration on most measured variables were significantly higher than its low concentration. The effects of highest concentration of the extract also on some variables were significantly higher than its medium concentration. In addition, the effects of the high concentration of ALA on most variables were also higher than the effects of its low concentration. The concentration dependency effect of the extract and ALA on antioxidant and oxidant biomarkers as well as on total and differential WBC also support their anti-inflammatory and antioxidant effects on rat animal model of asthma.

The results of the present study showed increased lymphocyte percent in sensitized and its reduction in treated groups. However, this finding is perhaps due to increased total WBC in sensitized animals and reduction of total WBC in treated groups. In fact, increased number of the lymphocyte using similar method of animal sensitization was reported previously.⁶⁰

In the previous studies also, anti-inflammatory and anti-oxidant effects of *P. oleracea*^{19,20} and alpha linolenic acid³³, were reported, which support the observed effects of the plant and its constituent on sensitized rats in the present study. Potent antioxidant effect of purslane by decreasing enzyme activities and its effect against oxidative stress have been reported.⁶¹ Ethanolic extract of the *P. oleracea*, showed significant analgesic and anti-inflammatory activities, when compared with synthetic drugs.¹⁹ Increased levels of GPx, GR, GST, CAT and SOD, were all found to correlate with elevated glutathione level and decreased MDA and NO in rats due to *P. oleracea* and ALA treatment were also shown.⁶² ALA treatment also lead to reduction of TNF- α and IL-6/IL-8, which are involved in the inflammation process.⁶³ Our previous study also indicated reduction in total and differential WBC count in sensitized guinea pigs treated with an anti-inflammatory drug^{60,64}, which supports the results of the present study. Therefore, these results suggest that the extract of *P. oleracea* and ALA may have preventive effects on asthma disease by reduction of oxidative stress, inflammatory cells and airway

inflammation.

The effects of low concentration of ALA on several measured parameters were significantly higher than the effects of corresponding concentrations of the extract. However, the effect of high concentration of ALA only on serum level of CAT and lymphocyte percentage was higher than the effects of corresponding extract concentrations. The studied concentrations of ALA in the present study were one tenth (10%) of those of the extract of *P. oleracea* (0.2 and 0.4 mg/mL for ALA and 1 and 4 mg/mL for low and high concentrations of the extract). It was shown that the amount of ALA in 100 grams of fresh dry plant is about 300-400 mg or about 0.4%⁶⁵, which is much lower than the studied concentrations of ALA used in the present study. These results showed that ALA is only partially responsible for anti-inflammatory and antioxidant effects of the extract of *P. oleracea* in sensitized rats.

The effect of low concentration of the extract and ALA on most measured variables were lower than the effect of dexamethasone treatment. However, the effects of high concentration of the extract and ALA were not statistically different from the effect of dexamethasone or even were significantly higher than dexamethasone treatment group (serum NO₂ level, eosinophil and lymphocyte percentage). These antioxidant and anti-inflammatory effect of the extract and its constituent ALA in sensitized rats, which is comparable to the effect of dexamethasone also support these effectiveness of the plant and ALA.

The present study as well as other similar studies^{19,20,30,34,36} indicate anti-inflammatory and antioxidant effects of *P. oleracea* and alpha linolenic acid, which could have a therapeutic effect on inflammatory diseases such as asthma by reduction of lung inflammation. However, further studies are needed to evaluate the effect of this plant and its constituent ALA as well as the effect of other constituents of the plant on asthmatic patients.

In conclusion, the results of this study showed a preventive effect of the extract of *P. oleracea* and its constituent alpha linolenic acid on inflammatory cells and serum oxidant, antioxidant levels in sensitized rats comparable to the effect of dexamethasone at used concentrations. The results also suggest that the effect of the plant is perhaps due to its constituent, ALA.

ACKNOWLEDGEMENTS

This study was financially supported by a grant from Islamic Azad University, Mashhad Branch. The results described in this paper were part of the PhD student thesis of Mahsa Kaveh.

REFERENCES

1. Koh GC, Shek LP, Goh DY, Bever H, Koh DS. Eosinophil cationic protein: Is it useful in asthma? A systematic review. *Respir Med* 2007; 101(4):696-705.
2. Chanez P, Dent G, Yukawa T, Barnes PJ, Chang KF. Generation of oxygen free radicals from blood eosinophils from asthma patients after stimulation with PAF or phorbol ester. *Eur Respir J* 1990; 3(9):1002-7.
3. Cluzel M, Damon M, Chanaz P, Bonsquet J, Crastesde Paulet A, Michel FB, et al. Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. *J Allergy Clin Immunol* 1987; 80(2):195-201.
4. Calhoun WJ, Salisbury SM, Bush RK, Busse WW. Increased superoxide release from alveolar macrophages in symptomatic asthma. *Am Rev Respir Dis* 1987; 135:A224.
5. Vachier I, Damon M, Le Doucen C, De Paulet AC, Chanez P, Michel FB, et al. Increased oxygen species generation in blood monocytes of asthma patients. *Am Rev Respir Dis* 1992; 146(5):1161-6.
6. Heffner JE, Repine JE. Antioxidants and the lung. In: Crystal RG, West WB, editor. *The lung: scientific foundations*. New York: Raven Press 1991:1811-20.
7. Van Asbeck BS, Hoidal J, Vercelloti GM, Schwartz BA, Moldow CF, Jacob HS. Protection against lethal hyperoxia by tracheal insufflation of erythrocytes: role of red cell glutathione. *Science* 1985; 227(4688):756-9.
8. Agar NS, Sadraideh SM, Hallaway PE, Eaton JW. Erythrocyte catalase. A somatic oxidant defense. *J Clin Invest* 1986; 77(1):319-21.
9. Toth KM, Clifford DP, Berger EM, White CW, Repine JE. Intact human erythrocyte prevent hydrogen peroxide mediated damage to isolated perfused rat lungs and cultured bovine pulmonary artery endothelial cells. *J Clin Invest* 1984; 74(1):292-5.
10. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD and smokers. *Am J Respir Crit Care Med* 1996; 154(4):1055-60.
11. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. *Lipids* 2000; 35(9):967-74.
12. Chanez P, Dent G, Yukawa T, Barnes PJ, Chang KF. Generation of oxygen free radicals from blood eosinophils from asthma patients after stimulation with PAF or phorbol ester. *Eur Respir J* 1990; 3(9):1002-7.
13. Vachier I, Damon M, Le Doucen C, De Paulet AC, Chanez P, Michel FB, et al. Increased oxygen species generation in blood monocytes of asthma patients. *Am Rev Respir Dis* 1992; 146(5):1161-6.
14. Kelly FJ, Mudway L, Blomberg A, Frew A, Sandstorm T. Altered lung antioxidant status in patients with mild asthma. *The Lancet* 1999; 354(9177):482-3.
15. Kharitinov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. *The Lancet* 1994; 343(8890):133-5.
16. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalyaci O. Oxidative stress and antioxidant defense. *World Allergy Organ J* 2012; 5(1):9-19.
17. Shane-McWhorter L. Botanical dietary supplements and the treatment of diabetes: what is the evidence? *Curr Diab Rep* 2005; 5(5):391-8.
18. Elkhayat ES, Ibrahim SR, Aziz MA. Portulene, a new diterpene from *Portulaca oleracea* L. *J Asian Nat Prod Res* 2008; 10(11):1039-43.
19. Chan K, Islam MW, Kamil M et al. The analgesic and anti-inflammatory effects of *Portulaca oleracea* L. subsp. *Sativa* (Haw.) Celak. *Journal of Ethnopharmacology* 2000; 73(3):445-451.
20. Chen B, Zhou H, Zhao W, Zhou W, Yuan Q, Yang G. Effects of aqueous extract of *Portulaca oleracea* L. on oxidative stress and liver, spleen leptin, PAR α and FAS mRNA expression in high-fat diet induced mice. *Mol Biol Rep* 2012; 39(8):7981-88.
21. Rashed AN, Afifi FU, and Disi AM. Simple evaluation of the wound healing activity of a crude extract of *Portulaca oleracea* L. (growing in Jordan) in *Mus musculus* JVI-1. *J Ethnopharmacol* 2003; 88(2-3):131-6.
22. Parry O, Okwuasaba Fk, Ejike C. Skeletal muscle relaxant action of an aqueous extract of *Portulaca oleracea* in the rat. *J Ethnopharmacol* 1987; 19(3):247-53.
23. Boskabady MH, Brushaki MT, Aslani MR. Relaxant effect of *Portulaca oleraceae* on guinea pig tracheal chains and its possible mechanism(s) of action. *Med Hypothesis Res* 2004; 1(2/3):139-47.
24. Hashemzahi M, Khazdair MR, Kiyannmehr M, Askari VR, Boskabady MH. *Portulaca oleracea* Affects Muscarinic Receptors of Guinea Pig Tracheal Smooth Muscle. *Ind J*

Anti-oxidant and Anti-inflammatory Effect of *Portulaca oleracea*, in Sensitized Rat

- Pharmac Sci 2016; 78(3):388-94.
25. Malek F, Boskabady MH, Borushaki MT, Tohidi M. Bronchodilatory effect of *Portulaca oleracea* in airways of asthmatic patients. J Ethnopharmacol 2004; 93(1):57-62.
 26. Boroushaki MT, Boskabady MH, Malek F. Antitussive effect of *Portulaca oleracea* L. in guinea pigs. Iran J Pharm Res 2004; 3(3):187-190.
 27. Askari VR, Rezaee SA, Abnous K, Iranshahi M, Boskabady MH. The Influence of Hydro-Ethanollic Extract of *Portulaca oleracea* on Th1/Th2 balance in Isolated Human Lymphocytes. J Ethnopharmacol 2016; 194:1112-21.
 28. Palaniswamy UR, McAvoy RJ, Bible BB. Stage of harvest and polyunsaturated essential fatty acid concentrations in purslane (*Portulaca oleracea*) leaves. J Agric Food Chem 2001; 49(7):3490-3.
 29. Arruda SF, Siqueira EMA, Souza EMT. Malanga (*Xanthosoma sagittifolium*) and purslane (*Portulaca oleracea*) leaves reduce oxidative stress in vitamin A-deficient rats. Ann Nutr Metab 2004; 48(4):288-95.
 30. Yang Z, Liu C, Xiang L, Zheng Y. Phenolic alkaloids as a new class of antioxidants in *Portulaca oleracea*. Phytother Res 2009; 23(7):1032-5.
 31. Abdel Moneim AE, Dkhil MA, Al-Quraishy S. The potential role of *Portulaca oleracea* as a neuroprotective agent in rotenone-induced neurotoxicity and apoptosis in the brain of rats. Pesticide Biochemistry and Physiology 2013; 105(3):203-212.
 32. Uddin MK, Juraimi AS, Hossain MS, Nahar MAU, Ali ME, Rahman MM. Purslane Weed (*Portulaca oleracea*): A Prospective Plant Source of Nutrition, Omega-3 Fatty Acid, and Antioxidant Attributes. ScientificWorldJournal 2014; 2014:951019.
 33. Valivety R, Gill I. Polyunsaturated fatty acids, Part 1: occurrence, biological activities and applications. Trends Biotechnol 1997; 15(10):401-9.
 34. Mccusker MM, Grant-Kels JM. Healing fats of the skin: the structural and immunologic roles of the ω -6 and ω -3 fatty acids. Clin Dermatol 2010; 28(4):440-51.
 35. Arm JP, Horton CE, Spur BW, Mencia-Huerta JM, Lee TH. The effects of dietary supplementation with fish oil lipids on the airways response to inhaled allergen in bronchial asthma. Am Rev Respir Dis 1989; 139(6):1395-400.
 36. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Van Der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320(5):265-271.
 37. Salmon M, Walsh D, Huang T, Barnes P, Leonard T, Hay D, et al. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J Pharmacol 1999; 127(5):1151-8.
 38. Hosseinzadeh H, Sadeghnia HR. Safranal, a constituent of *Crocus sativus* (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. J Pharm Pharm Sci 2005; 8(3):394-399.
 39. Madesh M, Balasubramanian KA. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J Biochem Biophys 1998; 35(3):184-8.
 40. Beers RF Jr, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952; 195(1):133-40.
 41. Yousefniapasha Y, Jorsaraei G, Gholinezhadchari M, Mahjoub S, Hajiahmadi M, Farsi M. Nitric Oxide Levels and Total Antioxidant Capacity in The Seminal Plasma of Infertile Smoking Men. Cell J 2015; 17(1):129-36.
 42. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Bio Med 1990; 9(6):515-40.
 43. Hall ED, Bosken JM. Measurement of oxygen radicals and lipid peroxidation in neural tissues. Curr Protoc Neurosci 2009; 17:1-51.
 44. Kanazawa H, Shoji S, Yoshikawa T, Hirata K, Yoshikawa J. Increased production of endogenous nitric oxide in patients with bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 1998; 28(10):1244-50.
 45. Ricciardolo FL, Nijkamp FP, Folkerts G. Nitric oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease. Curr Drug Targets 2006; 7(6):721-35.
 46. Gutierrez HH, Nieves B, Chumley P, Rivera A, Freeman BA. Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. Free Radic Biol Med 1996; 21(1):43-52.
 47. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995; 16(3):128-30.
 48. Ahmad A, Shameem M, Husain Q. Relation of oxidant-antioxidant imbalance with disease progression in patients with asthma. Ann Thorac Med 2012; 7(4):226-32.

49. Corradi M, Pignatti P, Manini P, Andreoli R, Goldoni M, Poppa M, Moscato G, Balbi B, Mutti A. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. *Eur Respir J* 2004; 24(6):1011–7.
50. Luksza AR, Jones DK. Comparison of whole-blood eosinophil counts in extrinsic asthmatics with acute and chronic asthma. *Br Med J* 1982; 285(6350):1229-31.
51. Boskabady MH, Jalali S. Effect of *Zataria multiflora* extract on total and differential white blood cell count and endothelin level in blood of ovalbumin sensitized guinea pigs. *Chin J Integr Med* 2016.
52. Robroeks CM, Van de Kant KD, Jobsis Q, Hendriks HJ, Van Gent R, Wouters EF, et al. Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma. *Clin Exp Allergy* 2007; 37(9):1303–11.
53. Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. *FASEB J* 1998; 12(11):929–37.
54. Fatani SH. Biomarkers of Oxidative Stress in Acute and Chronic Bronchial Asthma. *J Asthma* 2014; 51(6):578-84.
55. Zanatta AL, Junior PV, Nishiyama A. The prevention of oxidative stress improve asthmatic inflammation. *Adv Biosci Biotechnol* 2012; 3(8):1087-90.
56. Filley WV, Kephart GM, Holley KE, Gleich GJ. Identification by immunofluorescence of eosinophil granule MBP in lung tissues of patients with bronchial asthma. *Lancet* 1982; 320(8288):11-6.
57. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma: relationship to disease severity and atopic status. *Am Rev Respir Dis* 1990; 141(4):970-7.
58. Riedl MA and Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. *Curr Opin Allergy Clin Immunol* 2008; 8(1):49-56.
59. Tang XY, Yu HP, Deng HJ, Chen X, Fan HZ, Gong YX, et al. Pathogenic mechanism of CD8(+)CD28(-)T cell and the effect of dexamethasone in asthmatic mouse. *Zhonghua Yi Xue Za Zhi* 2011; 91(26):1861-5.
60. Keyhanmanesh R, Boskabady MH, Eslamizadeh MJ, Khamneh S, Ebrahimi MA. The effect of thymoquinone, the main constituent of *Nigella sativa* on tracheal responsiveness and WBC count in lung lavage of sensitized guinea pigs. *Planta Med* 2010; 76(3):218–22.
61. Mohamed AI, Hussein AS. Chemical composition of purslane (*Portulaca oleracea*). *Plant Foods Hum Nutr* 1994; 45(1):1-9.
62. Dkhil MA, Abdel Moniem AE, Al-Quraishy S, Awadallah Saleh Reda. Antioxidant effect of purslane (*Portulaca oleracea*) and its mechanism of action. *J Med Plant Res* 2011; 5(9):1563-89.
63. Xie N, Zhang W, Li J, Liang H, Zhou H, Duan W, et al. Alpha-linolenic acid intake attenuates myocardial ischemia/reperfusion injury through anti-inflammatory and anti-oxidative stress effects in diabetic but not normal rats. *Arch Med Res* 2011; 42(3): 171–181.
64. Boskabady MH, Jalali S. Effect of carvacrol on tracheal responsiveness, inflammatory mediators, total and differential WBC count in blood of sensitized guinea pigs. *Exp Biol Med* 2013; 238(2):200-8.
65. Simopoulos AP, Norman HA, Gillaspay JE, Duke JA. Common purslane: a source of omega-3 fatty acids and antioxidants. *J Am Coll Nutr* 1992; 11(4):374-82.